COLOPLAST

Coloplast’s share dropped 3.3% and fell intraday to as low as 427.8 DKK after JPMorgan cut its rating from "Neutral" to "Underweight" and lowered the December 2027 price target from 484 DKK to 377 DKK (about −22%). The bank cited a high P/E ratio of 35.35 and a valuation premium of roughly 20% versus the medtech sector, while earnings growth lags the industry. JPMorgan also noted governance uncertainty and expects the new CEO is likely to revise mid‑term financial targets down when results are presented on 3 November; weak Q3 margins and increased short interest add further pressure. » Más en de.investing.com

Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » Más en finanzen.net

Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » Más en finanzen.net